The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial.
 
Jaekyung Cheon
Consulting or Advisory Role - Eisai; Roche
Speakers' Bureau - Eisai; SERVIER
Research Funding - Bayer
 
Baek-Yeol Ryoo
No Relationships to Disclose
 
Beodeul Kang
No Relationships to Disclose
 
Hongjae Chon
Consulting or Advisory Role - AstraZeneca; Bayer; BMS; Celgene Cancer Care Links/BMS; Eisai; Green Cross; Menarini; MSD Oncology; Ono Pharmaceutical; Roche; Sanofi; SERVIER; Sillajen
Speakers' Bureau - Bayer; BMS; Celgene/Bristol-Myers Squibb; Dong-A ST; Eisai; Menarini; Roche; Sanofi; SERVIER
Research Funding - Boryung (Inst); Dong-A ST (Inst); Roche (Inst)
 
Changhoon Yoo
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; MSD Oncology; SERVIER
Speakers' Bureau - Bayer; Celgene; Eisai; Ipsen; Merck Sharp & Dohme; Novartis
Research Funding - AstraZeneca; Bayer; CKD pharm; SERVIER